D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$820M |
| 2 |
Visa
V
|
+$667M |
| 3 |
HES
Hess
HES
|
+$515M |
| 4 |
Mastercard
MA
|
+$425M |
| 5 |
Oracle
ORCL
|
+$382M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.03B |
| 2 |
Advanced Micro Devices
AMD
|
+$949M |
| 3 |
Citigroup
C
|
+$419M |
| 4 |
ExxonMobil
XOM
|
+$391M |
| 5 |
Booking.com
BKNG
|
+$349M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 40.59% |
| 2 | Technology | 18.36% |
| 3 | Consumer Discretionary | 9.46% |
| 4 | Financials | 6.95% |
| 5 | Healthcare | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2576
Ambev
ABEV
$45.8B
| $1.81M | ﹤0.01% |
+729,107
| New | +$1.9M |
|
2577
CALL
Spectrum Brands
SPB
$1.98B
| $1.81M | ﹤0.01% |
20,300
| – | – |
|
2578
Immunovant
IMVT
$7.66B
| $1.81M | ﹤0.01% |
55,914
-52
| -0.1% | -$1.9K |
|
|
GBIO
2579
DELISTED
Generation Bio
GBIO
| $1.81M | ﹤0.01% |
44,371
+16,060
| +57% | +$378K |
|
2580
ePlus
PLUS
$2.36B
| $1.8M | ﹤0.01% |
22,956
-35,332
| -61% | -$2.75M |
|
2581
CALL
Colgate-Palmolive
CL
$69.5B
| $1.8M | ﹤0.01% |
20,000
| – | – |
|
|
2582
PUT
Colgate-Palmolive
CL
$69.5B
| $1.8M | ﹤0.01% |
20,000
| – | – |
|
2583
CEVA Inc
CEVA
$836M
| $1.8M | ﹤0.01% |
79,222
-2,363
| -3% | -$51.6K |
|
2584
Design Therapeutics
DSGN
$785M
| $1.8M | ﹤0.01% |
446,190
+155,562
| +54% | +$415K |
|
2585
Organogenesis Holdings
ORGO
$176M
| $1.8M | ﹤0.01% |
632,744
-334,128
| -35% | -$1.14M |
|
2586
Lands' End
LE
$301M
| $1.8M | ﹤0.01% |
164,854
-14,341
| -8% | -$131K |
|
2587
PetMed Express
PETS
$34.7M
| $1.79M | ﹤0.01% |
374,021
+234,362
| +168% | +$1.36M |
|
2588
Aldeyra Therapeutics
ALDX
$82M
| $1.79M | ﹤0.01% |
547,640
+287,584
| +111% | +$946K |
|
2589
Fossil Group
FOSL
$325M
| $1.79M | ﹤0.01% |
1,754,669
-69,744
| -4% | -$77.8K |
|
2590
MGM Resorts International
MGM
$9.45B
| $1.79M | ﹤0.01% |
37,818
+21,865
| +137% | +$956K |
|
2591
CALL
ZTO Express
ZTO
$15.8B
| $1.78M | ﹤0.01% |
85,000
-65,000
| -43% | -$1.24M |
|
2592
CALL
Ball Corp
BALL
$16B
| $1.78M | ﹤0.01% |
26,400
| – | – |
|
|
FORL
2593
DELISTED
Four Leaf Acquisition Corp
FORL
| $1.78M | ﹤0.01% |
165,000
| – | – |
|
2594
Revolve Group
RVLV
$1.47B
| $1.77M | ﹤0.01% |
83,770
-53,596
| -39% | -$940K |
|
2595
PUT
ZIM Integrated Shipping Services
ZIM
$3.61B
| $1.77M | ﹤0.01% |
175,000
+100,000
| +133% | +$1.21M |
|
2596
PUT
AGNC Investment
AGNC
$11.7B
| $1.77M | ﹤0.01% |
178,700
-301,300
| -63% | -$2.91M |
|
2597
CALL
Canadian Pacific Kansas City
CP
$77B
| $1.76M | ﹤0.01% |
+20,000
| New | +$1.68M |
|
2598
Wave Life Sciences
WVE
$857M
| $1.76M | ﹤0.01% |
+285,092
| New | +$1.43M |
|
|
ACLX
2599
DELISTED
Arcellx
ACLX
| $1.76M | ﹤0.01% |
25,286
-41,788
| -62% | -$2.65M |
|
2600
PUT
Aflac
AFL
$58.1B
| $1.75M | ﹤0.01% |
20,400
-2,100
| -9% | -$172K |
|
Similar funds
D.E. Shaw & Co's Q1 2024 Portfolio in Review
As of Q1 2024, D.E. Shaw & Co held 4,923 positions worth $117B, up 2.1% from $114B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
D.E. Shaw & Co's Q1 2024 filing shows 655 new, 1,367 increased, 1,722 reduced and 634 closed positions. Its largest new stake was Arm: 2,379,839 shares worth $297M. The largest sale was NVIDIA, an estimated $1.03B.
By sector, the portfolio is most concentrated in Miscellaneous at 41% of assets, down from 46% a quarter earlier, followed by Technology and Consumer Discretionary.
- D.E. Shaw & Co's largest Q1 2024 buy was Arm: 2,379,839 shares worth $297M.
- D.E. Shaw & Co added most to Apple in Q1 2024, an estimated $820M increase.
- D.E. Shaw & Co's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $1.03B.
- D.E. Shaw & Co fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q1 2024, selling an estimated $307M.
- D.E. Shaw & Co's ten largest holdings make up 13% of its $117B portfolio in Q1 2024.
- D.E. Shaw & Co opened 655 new positions and closed 634 in Q1 2024.
- D.E. Shaw & Co's portfolio value rose 2.1% quarter-over-quarter to $117B.
Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.